Company Filing History:
Years Active: 2021
Title: Sam Hsien-I Shen: Innovator in Hemostasis Therapy
Introduction
Sam Hsien-I Shen, based in Iowa City, IA, is a notable inventor whose work focuses on advancing treatments for hemostasis disorders. With a patented innovation under his name, he is contributing to the medical field in significant ways.
Latest Patents
Sam's most recent patent is titled "CpG reduced factor VIII variants, compositions and methods and uses for treatment of hemostasis disorders." This patent introduces CpG reduced nucleic acid variants that encode the FVIII protein. The technology disclosed demonstrates improved efficiency in expression by cells, higher secretion levels compared to wild-type Factor VIII proteins, and enhanced performance in terms of activity and packaging into viral vectors.
Career Highlights
Currently, Sam is employed at Spark Therapeutics, Inc., where he applies his expertise in developing innovative therapies. His significant contributions to the field of hemostasis are underpinned by his dedication to improving health outcomes for patients with coagulation disorders.
Collaborations
Throughout his career, Sam has collaborated with fellow innovator Xavier Anguela. Their partnership highlights the importance of teamwork in the research and development of new therapies aimed at addressing complex medical challenges.
Conclusion
Sam Hsien-I Shen is an impactful inventor whose patent on CpG reduced factor VIII variants is poised to make a substantial difference in the realm of hemostasis disorder treatments. With his work at Spark Therapeutics, Inc. and fruitful collaborations, he continues to push the boundaries of innovation in healthcare.